Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15523 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Courtney N Haller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas, USA. Hauptthemen laut MEDLINE: Pyridones, Pyrimidinones, Skin Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIH/NIAMS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
We present the case of a 20‐month‐old girl with Schimmelpenning‐Feuerstein‐Mims (SFM) syndrome with extensive head, neck, and torso skin involvement successfully managed with topical trametinib. Trametinib interferes downstream of KRAS and HRAS in the MAPK signaling pathway, of which KRAS was implicated in our child's pathogenic variant. Although other dermatologic conditions have shown benefit from oral trametinib, its topical use has not been well reported. Our patient showed benefit from the use of twice‐daily topical trametinib, applied to the epidermal and sebaceous nevi over a 16‐month period, leading to decreased pruritus and thinning of the plaques.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Dermatology, Dell Medical School, University of Texas, Austin, Texas, USA.
- Department of Dermatology, Baylor Scott and White, Temple, Texas, USA.
- Chemistry Rx Compounding and Specialty Pharmacy, Folcroft, Pennsylvania, USA.
- Drug Dynamics Institute, College of Pharmacy, The University of Texas, Austin, Texas, USA.
- Department of Chemistry, The University of Texas, Austin, Texas, USA.
- Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Maria A Leszczynska, Lars Brichta
Förderung
- NIAMS NIH HHS
- NIH/NIAMS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Haller, C. N., Leszczynska, M. A., Brichta, L., Maier, E., Riddington, I. M., Choate, K. A., & Levy, M. L. (2024). Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome. Pediatric Dermatology. https://doi.org/10.1111/pde.15523
Vancouver
Haller CN, Leszczynska MA, Brichta L, Maier E, Riddington IM, Choate KA, et al. Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome. Pediatric Dermatology. 2024. doi:10.1111/pde.15523
BibTeX
@article{Haller2024,
author = {Haller, Courtney N and Leszczynska, Maria A and Brichta, Lars and Maier, Esther and Riddington, Ian M and Choate, Keith A and Levy, Moise L},
title = {Topical trametinib for epidermal and sebaceous nevi in a child with Schimmelpenning‐Feuerstein‐Mims syndrome},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15523}
}
EUVIMED